JAMA Cardiology publishes RHYTHM Study Revealing L

SAN FRANCISCO, May 16, 2018 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC ), a leading digital health care solutions company focused on the advancement of cardiac care, today announced results of a study which utilized Zio by iRhythm, an extended continuous cardiac monitoring system, to provide a comprehensive picture of the burden of atrial fibrillation (AF) in patients. Utilizing this data in combination with electronic health record data, the researchers concluded that an increase in the burden of atrial fibrillation (AF) is independently associated with a higher risk of ischemic stroke and arterial thromboembolism in patients who are not taking anticoagulant medication. The findings have been published in JAMA Cardiology .

The study, the Kaiser Permanente Real-World Heart Monitoring Strategy Evaluation Treatment Patterns and Health Metrics in Atrial Fibrillation (KP-RHYTHM) study, derived its findings from a retrospective cohort of 1,965 patients at two large integrated health care delivery systems who underwent up to 14 days of continuous ambulatory electrocardiogram (ECG) monitoring using Zio by iRhythm and were found to have paroxysmal (intermittent) AF. By using Zio by iRhythm to measure heart rhythm, the researchers were able to overcome limitations of previous studies which only looked at patients undergoing cardiac monitoring via invasive and expensive devices.  

True AF burden™, as detected and measured by the Zio Service, gives physicians a comprehensive understanding of the amount of time a patient’s heart spends in AF over the extended monitoring period given Zio’s longer wear time and ability to bridge AF episodes that may be separated by noise or artifact. The results of the study show that the total burden of AF was the key indicating factor for stroke risk, as opposed to longer individual AF episodes with smaller overall burden. The results show that an AF burden lasting more than 11% of the total time their heart rhythm was monitored was found to be associated with a 3-fold increase in stroke risk, independent of other known risk factors in those patients.

“There is an emerging recognition of the importance of AF burden as a potentially better measure of stroke risk, which is underscored by the recent AHA Scientific Statement ‘Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity’,” said Dr. Elsayed Z. Soliman Professor and Director, Epidemiological Cardiology Research Center, Wake Forest University School of Medicine, Winston Salem, NC. “Studies like the KP-RHYTHM study demonstrate how advances in cardiac monitoring technology enhance our understanding of AF burden, which could help improve the current standards of care and improve patient outcomes.”

Strokes associated with AF tend to be more severe and are associated with higher mortality. By providing a deeper understanding of the link between burden of AF with risk of stroke, this study can have a direct impact on clinical decision making to prevent stroke, as it provides another stroke risk indicator that physicians can evaluate and share with their patients while discussing stroke prevention.

“We are proud that Zio by iRhythm’s extended continuous cardiac monitoring capability coupled with our algorithm’s ability to bridge AF episodes allowed the researchers to develop new insights, as it gave the researchers a more comprehensive picture of AF burden than has been available previously,” said Judy Lenane, RN, MHA, Executive Vice President of Operations and Chief Clinical Officer of iRhythm and one of the authors of the study. “This study adds to the growing body of research showing Zio by iRhythm has practical implications for clinical care. It is an important tool that helps physicians achieve certainty in a single test and accelerates care for their patients.”

The research was led by Dr. Alan Go, Chief, Cardiovascular and Metabolic Conditions Research at Kaiser Permanente. JAMA Cardiology is a peer-reviewed journal dedicated to publishing exceptional original research, state-of-the-art reviews, and informative opinion that will advance the science and practice of cardiology, enhance cardiovascular health, and inform health care policy.

You can learn more about the study and AF burden at  www.AFBurden.com .  

About iRhythm Technologies, Inc. iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

Investor Relations Contact Lynn Pieper Lewis or Leigh Salvo (415) 937-5404 investors@irhythmtech.com Media Contact Cherise Adkins   (415) 486-3235 media@irhythmtech.com